| Mhiri, Chokri |
NCT03958877 / 2018-003008-38: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis |
|
|
| Active, not recruiting | 3 | 142 | Europe, US, RoW | BIIB017 (peginterferon beta-1a), PLEGRIDY, Interferon beta type 1a, Avonex | Biogen | Multiple Sclerosis, Relapsing-Remitting | 05/27 | 05/27 | | |
| Pandolfo, Massimo |
EFACTS, NCT02069509: Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies |
|
|
| Recruiting | N/A | 1200 | Europe, RoW | | European Friedreich's Ataxia Consortium for Translational Studies | Friedreich's Ataxia | 12/24 | 12/24 | | |
TRACK-FA, NCT04349514: A Natural History Study to TRACK Brain and Spinal Cord Changes in Individuals with Friedreich Ataxia |
|
|
| Active, not recruiting | N/A | 300 | Europe, Canada, US, RoW | Natural history | Monash University, University of Minnesota, RWTH Aachen University, University of Campinas, Brazil, Children's Hospital of Philadelphia, University of Florida, Friedreich's Ataxia Research Alliance, McGill University | Friedreich Ataxia | 10/25 | 10/25 | | |
| Recruiting | N/A | 3000 | Europe, Canada, US, RoW | | Friedreich's Ataxia Research Alliance | Friedreich Ataxia | 01/48 | 01/48 | | |
| Tallaksen, Chantal ME |
| Recruiting | N/A | 300 | Europe | | Ataxia Study Group, German Center for Neurodegenerative Diseases (DZNE) | Late Onset Sporadic Cerebellar Ataxia | 12/30 | 12/30 | | |
| Crenier, Laurent |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
INLOOP, NCT06154135: Insulin Delivery Using the DBLG1 Closed-loop on Glycemic Control and PROMs in Adults Living With Type 1 Diabetes |
|
|
| Enrolling by invitation | N/A | 165 | Europe | | Erasme University Hospital | Diabetes Mellitus, Type 1 | 07/24 | 07/26 | | |
INRANGE, NCT04414280: The Impact of Hybrid Closed-loop Insulin Delivery in Type 1 Diabetes on Glycemic Control and PROMs |
|
|
| Recruiting | N/A | 1150 | Europe | Medtronic MiniMed 670G, Medtronic MiniMed 780G, Tandem Control-IQ | Universitaire Ziekenhuizen KU Leuven | Diabetes Mellitus, Type 1 | 12/24 | 12/24 | | |
| Franchimont, Denis |
SOPRANO-CD, NCT05169593: Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy |
|
|
| Recruiting | 4 | 292 | Europe | Biological Drug, Risankizumab, Vedolizumab, Ustekinumab, Infliximab, Adalimumab | Universitaire Ziekenhuizen KU Leuven | Crohn Disease | 10/27 | 10/30 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
| Jiang, Yi |
NCT05853718: Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women |
|
|
| Recruiting | 4 | 50 | RoW | Tenofovir Alafenamide Tablets, TAF | First People's Hospital of Hangzhou | Chronic Hepatitis b, Tenofovir Alafenamide Fumarate | 07/24 | 12/24 | | |
NCT06609447: The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis |
|
|
| Recruiting | 4 | 100 | RoW | VSL#3, Placebo, Placebo (for VSL#3), Vedolizumab, Vedolizumab 300 mg Injection | Second Affiliated Hospital, School of Medicine, Zhejiang University | Ulcerative Colitis | 12/27 | 12/27 | | |
| Completed | 3 | 1281 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828, Placebo | Eli Lilly and Company | Ulcerative Colitis | 01/21 | 05/24 | | |
|
|
|
|
| Completed | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
| Completed | 3 | 806 | Europe, Canada, US, RoW | Placebo, Mepolizumab | GlaxoSmithKline, PPD DEVELOPMENT, LP | Pulmonary Disease, Chronic Obstructive | 08/24 | 08/24 | | |
|
|
|
|
|
NCT04937387: Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma |
|
|
| Completed | 3 | 359 | RoW | FF/VI, FF/UMEC/VI, ELLIPTA | GlaxoSmithKline | Asthma | 08/24 | 08/24 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
RLDP, NCT05125081: Efficacy and Safety of Liuwei Dihuang Pill Versus Placebo in Presbycusis With Shen (Kidney)-Yin Deficiency |
|
|
| Recruiting | 2 | 120 | RoW | Liuwei Dihuang Pill (marketed product in China), Liu Wei Di Huang Pill, Liuwei Dihuang Pill（placebo ）, placebo group | Shanghai Jiao Tong University School of Medicine, Shanghai University of Traditional Chinese Medicine | Presbycusis, Age-related Hearing Loss, Hearing Disorders and Deafness | 11/24 | 12/24 | | |
SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. |
|
|
| Recruiting | 2 | 60 | RoW | SPH5030 | Shanghai Pharmaceuticals Holding Co., Ltd | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 12/26 | 12/26 | | |
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 238 | RoW | MRG003, Capecitabine tablets, Docetaxel injection | Shanghai Miracogen Inc. | Recurrent or Metastatic Nasopharyngeal Carcinoma | 10/24 | 02/25 | | |
NCT05867784: Effect of Vitamin D Supplementation on the Efficacy of Ustekinumab in the Treatment of Crohn's Disease |
|
|
| Completed | N/A | 80 | RoW | | Second Affiliated Hospital of Wenzhou Medical University | Ustekinumab, Vitamin D Supplementation, Crohn's Disease, Clinical Efficacy | 02/22 | 03/23 | | |
| Borne, Philippe van de |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT05391620: The Effect of the 3/7 vs 3X9 Method in Resistance Training on Metabolic Stress in Cardiac Rehabilitation |
|
|
| Completed | N/A | 25 | Europe | Cardiac rehabilitation with 3/7 method, 3/7 method, Cardiac rehabilitation with 3X9 method, 3X9 method | Université Libre de Bruxelles | Heart Failure, Resistance Training, Coronary Artery Disease | 06/22 | 10/22 | | |
NCT04772807: Validation of Kinocardiography, a New Technology Measuring Cardiac Mechanical Activity Via Accelerometers and Gyroscopes |
|
|
| Completed | N/A | 220 | Europe | Kinocardiograph, OKCARDIO smart application | Erasme University Hospital | Atrial Fibrillation, Hypertension, Heart Failure | 11/23 | 01/24 | | |
NCT06029881: Portable System for Non-intrusive Monitoring of Sleep |
|
|
| Not yet recruiting | N/A | 47 | Europe | Movesense MD | Erasme University Hospital, Fonds de la Recherche Scientifique (fnrs) | Sleep Apnea | 02/24 | 02/24 | | |
| Recruiting | N/A | 180 | Europe | Kinocardiography | Université Libre de Bruxelles, Erasme University Hospital | Aortic Valve Disease, Aortic Aneurysm | 03/25 | 09/25 | | |
| YILMAZ, Hasan Guney |
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Active, not recruiting | 2 | 271 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease | 12/25 | 03/26 | | |
| Eun, Chang Soo |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| ZHENG, Chang Qing |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| SZALAI, LASZLO |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Donets, Dmytro |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Cremer, Anneline |
| Completed | 4 | 200 | Europe | 5-ASA | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW, Ferring Pharmaceuticals | Ulcerative Colitis | 02/24 | 02/24 | | |
| Recruiting | 4 | 275 | Europe | Infliximab | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW, Celltrion | Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis | 05/26 | 11/26 | | |
| Pradhan, Rajesh |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06031844: A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP |
|
|
| Completed | 2 | 24 | Canada, US | DFV890, Placebo | Novartis Pharmaceuticals | Coronary Heart Disease | 12/24 | 12/24 | | |
| Recruiting | N/A | 650 | Europe, Canada, Japan, US, RoW | Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT) | Medtronic Cardiovascular | Moderate Aortic Valve Stenosis | 02/26 | 12/34 | | |
